Hous­ing As­traZeneca's old R&D ef­forts in an­tibi­otics, En­ta­sis files for $86M IPO

When As­traZeneca spun out its strug­gling an­tibi­otics unit a few years back, the tech — and a much small­er team — was de­posit­ed in­to a com­pa­ny called En­ta­sis. Now, that up­start has filed for an $86 mil­lion IPO to push a few of its prod­uct can­di­dates through hu­man tri­als.

The tiny Waltham com­pa­ny is on­ly a frac­tion of what the phar­ma gi­ant’s an­tibi­otics ef­fort used to be. At one point, the unit had 175 staffers. But it was pared down over the years un­til En­ta­sis launched in 2015 with on­ly 21 em­ploy­ees. To­day, ac­cord­ing to its prospec­tus, it em­ploys 34.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.